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The immune response against foreign pathogens 
must arise promptly, develop effectively, and 
end appropriately, to counteract infection and 
avoid injury to normal tissue. In autoimmu­
nity, however, the immune response is mis­
directed against self, resulting in tissue damage. 
Understanding  of  these  processes  has  been 
advanced  by  recognition  of  individual  cell 
types that carry out specific effector functions. 
Although the principal mission of B lymphocytes 
is considered to reside in immunoglobulin pro­
duction, an effector role for these cells in reg­
ulating  immune  activity  has  been  repeatedly 
noted (Zouali, 2008). With the recent success of 
B cell depletion therapy in autoimmune diseases, 
there is growing evidence that a population of 
cells contained within the B cell pool expresses 
immunostimulatory activity and  is  involved 
in clinical autoimmunity (Jacob and Stohl, 2010; 
Perosa et al., 2010; Sanz and Lee, 2010). Yet 
clear identification of the B cells that possess 
this function has remained a mystery.
B1 cells are a small innate B cell population 
that is responsible for constitutively producing 
protective natural immunoglobulin (Baumgarth, 
2011). In the mouse system B1 cells have been 
shown to arise early and to derive from a distinct 
progenitor, lending support to their status as a 
separate  lineage  in  a  layered  immune  system 
(Herzenberg  and  Tung,  2006;  Montecino­
Rodriguez et al., 2006). Current studies have 
revealed novel activities of B1 cells including, 
in particular, high level stimulation of T cell 
expansion (Zhong et al., 2007).
The recent identification of human B1 cells 
(Griffin et al., 2011) provides an opportunity 
to elucidate activities of this B cell population 
that may contribute to immune function and 
autoimmune disease. We found that human 
B1 cells are divisible into two readily separable, 
distinct populations and that T cell–stimulatory 
activity is a property of one population and   
not the other, which is instead characterized 
by heightened immunoglobulin secretion. The 
former, T cell–interacting population is mark­
edly increased in patients with lupus.
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A primary function of B lymphocytes is immunoglobulin production; however, the 
therapeutic benefit of B cell depletion in autoimmune diseases previously thought to be T cell 
mediated suggests that some B cells fulfill other roles in autoimmunity. We examined the 
recently identified human B1 cell population for T cell stimulatory activity. We found two 
kinds of B1 cells that are distinguished by multiple surface markers and distinct transcriptomic 
profiles. In both umbilical cord and adult peripheral blood, a CD11b+ subset constitutes 1 
out of every 8–10 B1 cells, whereas a CD11b subset constitutes the remaining B1 cells. 
These B1 cell populations differ functionally. CD11b B1 cells spontaneously secrete much 
more IgM than CD11b+ B1 cells. In contrast, CD11b+ B1 cells express more CD86, and more 
efficiently stimulate allogeneic CD4+ T cell expansion, than CD11b B1 cells. The frequency 
of these CD11b+ B1 cells is markedly elevated in lupus patients. CD11b+ B1 cells in lupus 
patients express more CD86 and have increased T cell–stimulating activity in disease. This 
work distinguishes a novel, T cell–interacting B1 cell population whose abundance and 
activity may be a reflection of, and a therapeutic target in, autoimmune disease.
© 2011 Griffin and Rothstein  This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Figure 1.  CD11b expression divides human B1 cells into two phenotypically distinct subsets. (A) Adult peripheral blood mononuclear cells were 
immunofluorescently stained for CD20, CD27, CD43, and CD11b, and were then evaluated by flow cytometric analysis. Two gating strategies are shown 
using nuclear staining with Hoechst 33342 (Hoechst) and FSC-H by FSC-A doublet gating to separate CD20+CD27+CD43+ B1 cells into CD11b+ and 
CD11b populations for a representative adult blood sample with isotype control displayed for CD11b. (B) Adult peripheral blood and umbilical cord blood 
mononuclear cells were stained for IgD, CD14, CD11c, and CD5 in addition to CD20, CD27, CD43, and CD11b, and then evaluated by flow cytometric analysis. 
Expression of IgD, CD14, CD11c, and CD5 by naive (CD20+CD27CD43) and memory (CD20+CD27+CD43) B cells and by CD11b and CD11b+ B1 cells 
(CD20+CD27+CD43+) is shown for representative adult and cord blood samples (one of three each) with isotype control in solid gray. (C) RNA was prepared 
from sort-purified populations of naive (CD20+CD27CD43) and memory (CD20+CD27+CD43) B cells, and from CD11b and CD11b+ B1 cells 
(CD20+CD27+CD43+), obtained from three normal adult individuals for each B cell population and analyzed for gene expression by microarray. Expression 
levels for CD11b, CD14, and CD11c transcripts are shown in the form of a heat map. (D) Adult peripheral blood mononuclear cells were stained with fluorescent 
antibodies that recognize CD19, CD43, and CD11b and sorted into populations containing naive/memory B cells, CD11b+ B1 cells, and CD11b B1 cells. Sort-
purified B cells were then stained with a fluorescent antibody targeting CD14, fixed, adhered to poly-lysine–coated slides, and examined for immunofluorescence JEM Vol. 208, No. 13  2593
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sequentially at three wavelengths by confocal microscopy. Representative results from one of three comparable experiments are shown. (E) Adult periph-
eral blood mononuclear cells were stained for CD20, CD27, CD43, CD11b, and CD80 and were then evaluated by flow cytometric analysis. CD80 expression by 
naive (CD20+CD27CD43) and memory (CD20+CD27+CD43) B cells, and by CD11b+ and CD11b B1 cells (CD20+CD27+CD43+), is shown as colored lines, 
along with isotype control (solid gray). Representative results from one of three comparable experiments are shown. (F) Adult peripheral blood mono-
nuclear cells were stained for CD20, CD27, CD43, CD11b, and CD71 and were then evaluated by flow cytometric analysis. CD71 expression by naive 
(CD20+CD27CD43) and memory (CD20+CD27+CD43) B cells, and by CD11b+ and CD11b B1 cells (CD20+CD27+CD43+) and CD11b+CD20CD71+ cells, 
is shown as colored lines, along with isotype control (solid gray). Representative results from one of three comparable experiments are shown.
 
RESULTS AND DISCUSSION
Human B1 cells obtained from both umbilical cord and 
adult peripheral  blood  express  index  functional  features 
not expressed by other mature B cells and phenotype as 
CD20+CD27+CD43+CD70 (Griffin et al., 2011). In further 
study we have now found that B1 cells can be divided into 
two distinct populations by phenotypic criteria. Immuno­
fluorescent staining reveals that some CD20+CD27+CD43+ 
B1 cells express CD11b, whereas the bulk of B1 cells do not 
(Fig. 1, A and B). In view of evidence in the mouse system 
that B1 cells readily form aggregates (Ghosn et al., 2008), 
and the association of CD11b with the monocyte lineage, we 
verified that CD11b expression is an intrinsic property of 
some human B1 cells. We stained DNA with Hoechst 33342 
and then analyzed only those cells that were singlets (Fig. 1 A). 
With this approach, we established that among cells defined 
on the basis of having only one nucleus, a specific fraction 
coexpressed CD20, CD27, CD43, and CD11b. Separately, 
we exerted strict FSC­H by FSC­A doublet gating (Fig. 1 A) 
but, regardless of the level of restriction, CD11b+ B1 cells 
were readily identified in similar proportions within the B1 
population. Overall, we found that CD11b+ B1 cells repre­
sent 1 out of every 8–10 B1 cells for both adult peripheral 
blood (n = 67) and umbilical cord blood (n = 6) samples, 
with the remainder being CD11b negative.
Several phenotypic differences distinguish CD11b+ and 
CD11b B1 cells. Notably, CD11b+ B1 cells express CD14 
and  high  levels  of  CD11c,  whereas  other  B  cell  types 
(CD11b B1 cells, memory B cells, and naive B cells) do not 
(Fig. 1 B). The distinctive staining for CD11b, CD14, and 
CD11c  is  mirrored  in  the  unique  expression  of  CD11b, 
CD14, and CD11c transcripts (Fig. 1 C).
To  further  establish  expression  of  CD14  by  CD11b+  
B1 cells, we visualized single sort–purified B1 cells by con­
focal microscopy. Sort­purified CD11b+ B1 cells coexpressed 
CD19, CD43, and CD14 (Fig. 1 D). In addition, and as 
expected, nominally CD11b B1 cells were positive for CD19 
and CD43 but failed to express CD14 (Fig. 1 D). In contrast, 
naive and memory B cells, though positive for CD19, ex­
pressed neither CD43 nor CD14, as expected (Fig. 1 D).
Despite unique surface marker expression, CD11b+ B1 
cells are similar to CD11b B1 cells (and naive B cells) in being 
predominantly IgD+, whereas a majority of memory B cells 
are IgD negative. Surface immunoglobulin expression marks 
CD11b+ and CD11b B1 cells as B cells. It is highly unlikely 
that binding of anti­IgD, or binding of other antibodies to 
defining determinants, is nonspecific inasmuch as additional 
antibodies bound poorly (anti­CD80) to CD11b+ or CD11b 
B1 cells despite binding to memory B cells (Fig. 1 E), or did 
not bind at all (anti­CD71) to CD11b+ or CD11b B1 cells 
despite binding CD11b+CD20CD71+ cells (Fig. 1 F).
Unlike CD11b B1 cells that are mostly CD5+, the majority 
of CD11b+ B1 cells either do not express CD5 or express 
very low levels of CD5 (Fig. 1 B). These results show that 
identification by CD5 expression not only omits 1/4 of 
all B1 cells (Griffin et al., 2011) but preferentially omits in 
particular one of two B1 cell subpopulations.
In sum, elevated expression of CD11b, CD11c, and CD14 
constitutes a constellation of markers that defines a small 
subpopulation  of  B1  cells  that  is  operationally  CD11b+. 
Further evidence that CD11b+ and CD11b B1 cells represent 
distinct groups is provided by the many genes differentially 
expressed between these two populations (Fig. 2 A), a subset 
of which is displayed in heat map format for each individual 
sample tested (Fig. 2 B).
We further characterized CD11b+ and CD11b B1 cells by 
examining isolated populations purified by cell sorting as de­
scribed in Materials and methods. To avoid potential doublets, 
Ca2+ was depleted with 2 mM EDTA, dilute cell suspensions 
were agitated frequently, and strict doublet discrimination was 
used. We showed that sort­purified CD11b+ and CD11b B1 
cells were single cells without evidence of doublets by post­
sort  analysis  on  the  basis  of  nuclear  staining  with  Hoechst 
33342 and FSC­H by FSC­A discrimination (Fig. S1 A). In 
addition, we sorted Hoechst­stained cells in single droplets 
onto glass slides and showed the presence of only a single nucleus 
per event in >500 events examined by direct visualization with 
fluorescence microscopy (Fig. S1 B). Furthermore, sort­purified 
B1 cells, both CD11b+ and CD11b, were >95% viable by 
propidium iodide staining.
We examined CD11b+ and CD11b B1 cells by light 
microscopy  after  sort  purification. These  B1  cells  display 
typical  round  lymphocyte  morphology  without  dendritic 
projections or multilobulated nuclei, as seen in Wright­
Giemsa–stained images, much like other B cells (Fig. S1 C). 
Notably, there was no change in expression of CD11b when 
sort­purified CD11b+ and CD11b B1 cells were separately 
cultured, with CD11b expression remaining high on CD11b+ 
B1 cells and remaining low on CD11b B1 cells, suggesting 
that these populations are stable and not in the process of 
transitioning one to another (Fig. S1 A). Moreover, stimulation 
of sorted CD11b B1 cells with PMA plus ionomycin, SAC 
plus IL­2, or anti­Ig plus anti­CD40 failed to induce surface 
expression of CD11b (or CD14) despite up­regulation of 2594 CD11b+ human B1 cells and lupus | Griffin and Rothstein
blood, and memory (CD20+CD27+CD43) B cells from 
adult blood without stimulation for 5 d and assayed super­
natants for IgM by ELISA. We found that for both adult and 
cord blood samples, CD11b B cells secreted much more 
IgM  than  CD11b+  B1  cells  (Fig.  3,  A  and  B),  whereas 
CD11b+ B1 cells still secreted more IgM than non­B1 B 
cells. Thus, CD11b B1 cells are specialized for spontaneous 
secretion of IgM.
We then tested these two B1 cell populations for antigen 
presentation and T cell stimulation. We cultured irradiated, 
sort­purified CD11b+ and CD11b B1 cells, as well as irradi­
ated naive B cells, from adult and cord blood, and irradiated 
memory B cells from adult blood, with allogeneically mis­
matched CD4+ T cells for 5 d and evaluated DNA replication 
by measuring tritiated thymidine incorporation. We found 
that for both adult and cord blood samples, CD11b+ B1 cells 
stimulated T cell proliferation to a much greater extent than 
CD11b B1 cells (Fig. 3, C and D), whereas CD11b B1 cells 
in turn stimulated T cell proliferation to a greater extent than 
non­B1 B cells.
T cell stimulation by mouse B1a cells has been reported 
to be attributable to CD86 expression (Zhong et al., 2007). We 
found that among human adult peripheral blood B1 cells, ex­
pression  of  CD11b  correlated  with  expression  of  CD86 
(Fig. 3 E), and that a much higher percentage of CD11b+ B1 
cells expressed CD86 above isotype control values than did 
CD11b B1 cells or naive or memory B cells (Fig. 3 F). This 
increased level of CD86 was mirrored by a much higher level of 
CD86 transcripts in CD11b+ B1 cells (Fig. 3 G). Importantly, 
T cell stimulation induced by CD11b+ B1 cells was markedly 
reduced by anti­CD86 neutralizing antibody (Fig. 3 H). Thus, 
CD11b+ B1 cells are specialized for efficient stimulation of   
T cells across an allogeneic barrier, at least in part as a result of 
elevated expression of CD86.
The present results indicate that segregation of B1 cells 
according to CD11b expression is accompanied by func­
tional polarization reflected in two foundational features: 
one population, which expresses CD11b and is the smaller of 
the two, strongly stimulates T cells through CD86 but produces 
modest levels of secreted antibody; and, a second population, 
which is CD11b and is the larger of the two, secretes abun­
dant amounts of IgM but is less effective in stimulating T cells. 
Collectively, these findings indicate a unique division of   
labor between two subpopulations of human B1 cells, one of 
which is specialized for secretion of IgM, the other of which 
is specialized for interaction with T cells.
Induction of T cell proliferation across an allogeneic barrier 
is a surrogate for antigen presentation, and in this sense the 
combination of elevated CD86 expression and efficient T cell 
stimulation on the part of CD11b+ B1 cells may speak to a role 
in the generation of T cell abnormalities in autoimmune disease. 
To address this possibility, we phenotyped circulating B cells in 
15 patients with lupus and 67 normal controls (see Table S1 for 
patient characteristics). In lupus patients, as in normal controls, 
CD20+CD27+CD43+ B1 cells lacked CD70 expression and thus   
were readily recognizable as true B1 cells (Griffin et al., 2011). 
CD69 (unpublished data), indicating that CD11b+ B1 cells 
are not simply an activated version of CD11b B1 cells.
We  evaluated  sort­purified  CD11b+  and  CD11b  B1 
cells for two key features by which human B1 cells were 
originally defined—spontaneous IgM secretion and efficient 
T cell stimulation—to assess functional distinctions that might 
differentiate these subsets. We first tested these two B1 cell 
populations for spontaneous secretion of immunoglobulin. 
We cultured CD11b+ and CD11b B1 cells, as well as naive 
(CD20+CD27CD43) B cells, from both adult and cord 
Figure 2.  CD11b expression divides human B1 cells into two tran-
scriptionally distinct subsets. Gene expression microarray analysis 
was performed on RNA that was isolated from sort-purified naive 
(CD20+CD27CD43) and memory (CD20+CD27+CD43) B cells, and from 
CD11b and CD11b+ B1 cells (CD20+CD27+CD43+), obtained from three 
normal adult individuals for each B cell population. (A) The expression of 
coding transcripts with well established annotation (28,688) by CD11b+ 
and CD11b B1 cells is shown in the form of a Venn diagram. Transcripts 
differentially expressed twofold or greater by CD11b+ B1 cells are shown 
in light orange, transcripts differentially expressed twofold or greater by 
CD11b B1 cells are shown in pink, and transcripts expressed similarly by 
CD11b and CD11b+ B1 cells are represented by the dark orange overlap. 
(B) A representative set of genes demonstrating significant expression 
differences among B cell populations for each individual tested is displayed 
as a heat map along with gene designations.JEM Vol. 208, No. 13  2595
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We found that CD11b+ B1 cells underwent changes in   
lupus. We  found  overall  a  large,  approximately  fourfold   
increase in CD11b+ B1 cells (and only minimal changes in 
naive, memory, and CD11b B1 cells; Fig. 4, A–C). Both 
lupus patients and control subjects were mostly female and 
predominantly of either European or Asian descent, and mean 
ages were 36 and 51 yr, respectively. Moreover, differences 
in B cell composition, particularly the increased frequency of 
CD11b+  B1  cells,  were  similar  when  lupus  samples  were 
compared with samples from 15 of the 67 controls that were 
intentionally age­ and gender­matched (whose B cells con­
sisted of 66.4 ± 2.6% naive versus 60.2 ± 5.1%, 21.1 ± 2.2% 
memory versus 11.7 ± 2.1%, 9.1 ± 1.5% CD11b B1 versus 
16.1 ± 3.9%, and 0.7 ± 0.1% CD11b+ B1 cells versus 5.3 ± 
1.1%). Not only is the proportion of CD11b+ B1 cells in­
creased in lupus, but CD11b+ B1 cell expression of CD86 is 
increased as well. In lupus patients, as in normal controls, the 
frequency of CD86 expression by CD11b+ B1 cells far out­
weighed that of other B cell populations (Fig. 4 D), and at the 
same time the amount of CD86 on CD86+CD11b+ B1 cells, 
quantified by mean fluorescence intensity, was greater in sam­
ples from lupus patients as compared with normal controls 
(Fig. 4 E). Furthermore, B1 cell function is altered in lupus. 
We found that lupus CD11b+ B1 cells were more effective 
than normal CD11b+ B1 cells in stimulating T cells (Fig. 4 F). 
Thus, in combination with the marked increase in CD11b+ 
B1 cells associated with lupus, the increased efficiency of   
T cell stimulation, identified in vitro, would have the effect of 
markedly enhancing T cell activation and effector function in 
vivo. Because many of the lupus samples were obtained from 
patients with inactive disease, increases in CD11b+ B1 cell 
numbers, CD86 expression, and T cell stimulation could not be 
correlated with clinical flares; however, the consistency of lupus­
associated B1 cell abnormalities may suggest a fundamental 
disorder that drives disease regardless of its periodic inflamma­
tory intensity which may, in turn, relate to other factors.
Recognition of CD11b+ B1 cells as a new B cell type 
with distinct characteristics provides a potential explanation 
for prior observations regarding B cells in lupus. The increase 
in CD11b+ B1 cells, which express much higher levels of 
Figure 3.  CD11b expression divides human B1 cells into two func-
tionally distinct subsets. (A–D) Sort-purified populations of naive B cells 
(CD20+CD27CD43-), CD11b B1 cells (CD20+CD27+CD43+CD11b), and 
CD11b+ B1 cells (CD20+CD27+CD43+CD11b+) were obtained from adult 
peripheral blood and umbilical cord blood samples, and sort-purified 
memory (mem) B cells (CD20+CD27+CD43) were obtained from adult 
blood. (A and B) B cells were cultured at 106 cells per ml for 5 d, after 
which supernatants were evaluated for secreted IgM by ELISA. Mean val-
ues are shown along with lines indicating SEM for six adult blood samples 
(A) and four cord blood samples (B) for each population. (C and D) B cells 
were irradiated and co-cultured 1:2 with negatively selected allogeneic 
CD4+ T cells for 5 d, after which proliferation was measured by incorpora-
tion of tritiated thymidine during the last 8 h of triplicate cultures. Mean 
cpm values are shown, along with lines indicating SEM for four adult 
blood samples (C) and three cord blood samples (D) for each population. 
(E and F) Mononuclear cells from adult peripheral blood samples were 
immunofluorescently stained for CD20, CD27, CD43, CD11b, and CD86 
and were then evaluated by flow cytometric analysis. (E) Levels of CD86 
and CD11b expressed by gated CD20+CD27+CD43+ B1 cells in a represen-
tative adult peripheral blood sample are shown. Representative results 
from 1 of 15 comparable experiments are shown. (F) Mean values for the 
proportion of CD86+ cells among naive B cells (CD20+CD27CD43), 
memory (mem) B cells (CD20+CD27+CD43), CD11b (11b) B1 cells 
(CD20+CD27+CD43+CD11b), and CD11b+ (11b+) B1 cells 
(CD20+CD27+CD43+CD11b+) are shown with lines indicating SEM for  
15 adult blood samples. (G) RNA was prepared from sort-purified popula-
tions of naive B cells (CD20+CD27CD43), memory (mem) B cells 
(CD20+CD27+CD43), and CD11b and CD11b+ B1 cells (CD20+CD27+CD43+), 
obtained from three normal adult individuals for each B cell population, 
and analyzed for gene expression by microarray. Expression of CD86 tran-
scripts is shown for each population in the form of a heat map. (H) Sort-
purified and irradiated CD20+CD27+CD43+CD11b+ B1 cells were 
co-cultured with allogeneic CD4+ T cells, as in C, with (CD86 NA) or with-
out (normal) anti-CD86 neutralizing antibody. For anti-CD86–treated 
cultures, B1 cells were exposed to antibody for 1 h before addition of  
T cells. Mean cpm values are shown along with lines indicating SEM for 
three adult peripheral blood samples analyzed in sextuplicate.
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CD86 than other B cell populations, is consistent with the 
previous finding that CD86+ B cells are increased in lupus 
(Bijl et al., 2001). Furthermore, the increase in CD11b+ B1 
cells, which like memory B cells express CD27, could well 
be responsible for the reported lupus­associated increase in 
CD27+ B cells (Jacobi et al., 2008).
Our previous work identifying CD27/CD43 coexpressing 
B cells as B1 cells emphasizes the peril in designating particular 
phenotypic determinants as negative criteria; had CD43­
expressing cells been discarded, B1 cells would have been 
omitted from consideration along with myeloid and T cells. 
Our current work indicating important divisions within the 
human B1 cell population on the basis of CD11b expression, 
leading to the identification of CD11b+ B1 cells, is again pro­
pelled by expression of surface determinants not classically   
associated with B cell status. This experience suggests the value 
of focusing on positive identification without preconceived 
exclusionary criteria.
Notably, CD11b+ B1 cells are not the same as tissue­
based FcRH4+ memory B cells because those B cells are pre­
dominantly negative for IgD and CD27 (Ehrhardt et al., 2005), 
whereas circulating CD11b+ B1 cells are positive for IgD   
and CD27. CD11b+ B1 cells are not the same as circulating 
CD21lo B cells identified in CVID patients because those B 
cells express low levels of CD21 and CD27, and no CD23 
(Rakhmanov et al., 2009), whereas circulating CD11b+ B1 cells 
are strongly CD21 and CD27 positive and express CD23 
(unpublished data). CD11b+ B1 cells are not the same as cir­
culating MZ B cells because those B cells express low levels 
of  IgD  and  do  not  express  CD23  (Weller  et  al.,  2004), 
whereas circulating CD11b+ B1 cells express substantial levels 
of both. Thus, CD11b+ B1 cells constitute a distinct and 
unique human B cell population without known antecedent 
or parallel among human B cells.
Lupus autoimmune disease appears to result from a com­
plex state of immune system dysfunction to which B cells 
contribute through their influence on T cells, among other 
mechanisms (Jacob and Stohl, 2010; Perosa et al., 2010; Sanz and 
Lee, 2010). In addition to earlier work in mouse models sug­
gesting the importance of B cells in the pathogenesis of lupus 
(Reininger et al., 1996), the recent success of anti­CD20 therapy 
has further emphasized the role B cells play in initiating and/
or perpetuating autoimmune dyscrasias (Lund and Randall, 
2010). The impact of B cell depletion on T cell abnormalities 
has demonstrated that there is a relevant effect of B cells on   
T cell stimulation in the context of autoimmune disease (Stasi 
et al., 2007; Eming et al., 2008; Liossis and Sfikakis, 2008).   
T cell–stimulating function is just the activity that we have 
shown to be concentrated within the very small CD11b+  
B1 cell population, which expands greatly in lupus, up­regulates 
CD86  expression,  and  becomes  more  immunostimulatory. 
Figure 4.  CD11b+ human B1 cells are increased and functionally 
altered in patients with systemic lupus erythematosus.  
(A and B) Adult peripheral blood mononuclear cells from normal indi-
viduals and from patients with SLE were immunofluorescently stained  
for CD20, CD27, CD43, and CD11b, and were then evaluated by flow cyto-
metric analysis. Expression of CD11b is shown (black lines) on gated 
CD20+CD27+CD43+ B1 cells from a representative normal individual  
from among the 67 normal controls (A) and a representative SLE patient  
(B) with isotype control in solid gray. (C) Adult peripheral blood mononuclear 
cells from patients with SLE and from normal individuals were immuno-
fluorescently stained for CD20, CD27, CD43, and CD11b, and were then 
evaluated by flow cytometric analysis. The percentages of naive B  
cells (CD20+CD27CD43), memory (mem) B cells (CD20+CD27+CD43), 
CD11b (11b) B1 cells (CD20+CD27+CD43+CD11b), and CD11b+ (11b+) 
B1 cells (CD20+CD27+CD43+CD11b+), among all B cells in SLE patients  
(n = 15), were compared with the percentages of these populations 
among all B cells in normal controls (n = 67). Ratios between these  
values are expressed as fold change for B cell populations in SLE patients 
versus normal controls along with lines indicating SEM. (D and E) Adult 
peripheral blood mononuclear cells from 15 lupus patients were immuno-
fluorescently stained for CD20, CD27, CD43, CD11b, and CD86 and  
were then evaluated by flow cytometric analysis. (D) Mean values for  
the proportion of CD86+ cells among naive B cells (CD20+CD27CD43), 
memory (mem) B cells (CD20+CD27+CD43), CD11b (11b) B1  
cells (CD20+CD27+CD43+CD11b), and CD11b+ (11b+) B1 cells 
(CD20+CD27+CD43+CD11b+) are shown with lines indicating SEM (n = 15). 
(E) CD86 mean fluorescence intensity (MFI) was evaluated for CD11b+ B1 
cells from 15 randomly selected samples from among the 67 normal con-
trol (normal) and 15 lupus patient (SLE) adult peripheral blood samples. 
Mean values are displayed along with lines indicating SEM. (F) Sort- 
purified and irradiated CD11b+ B1 cells (CD20+CD27+CD43+CD11b+) from 
three randomly selected samples from among the 67 normal control (nor-
mal) and 3 lupus patient (SLE) peripheral blood samples were cultured 1:2 
in triplicate with negatively selected allogeneic CD4+ B cells for 5 d, after 
which proliferation was measured by incorporation of tritiated thymidine. 
Mean cpm values are shown along with lines indicating SEM.
 JEM Vol. 208, No. 13  2597
Brief Definitive Report
Post­sort  analysis  showed  <1%  CD3  positivity  for  sort­purified  CD19­ 
enriched B cells and <3% CD3 positivity for sort­purified mononuclear (not 
preenriched) B cells.
ELISA. Immunoglobulin secretion was determined by ELISA assay, as 
previously described (Griffin et al., 2011).
Allogeneic  stimulation. Naive CD4+ T cells were negatively selected 
from PBMC and co­cultured with sort­purified, irradiated B cells at a ratio 
of 2:1, as previously described (Griffin et al., 2011) For the allogeneic stimu­
lation assays shown in Fig. 3 (C and D), 50,000 B cells were seeded per well. 
For the allogeneic stimulation assays shown in Fig. 4 F, comparing lupus pa­
tients to normal controls, 1,000 B cells were seeded per well to accommo­
date the smaller cell numbers that could be obtained from lupus patient 
samples. In some experiments B cells were exposed to 10 µg/ml of neutral­
izing anti­CD86 antibody for 1 h before, and then during, co­culture. Cul­
tures were pulsed with 0.75 µCi [3H]thymidine for the last 8 h of 5­d 
cultures, and cpm was determined by scintillation counting.
Microarray analysis. RNA was isolated from sort­purified naive B cells 
(CD20+CD27CD43), memory B cells (CD20+CD27+CD43), CD11b+ 
B1  cells  (CD20+CD27+CD43+CD11b+),  and  CD11b  B1  cells  (CD20+ 
CD27+CD43+CD11b) from three normal individuals per subset, using   
the RNeasy plus Mini kit according to the manufacturer’s instructions   
(QIAGEN). RNA was analyzed for gene expression using the Illumina plat­
form. The human HT­12 v4 Expression BeadChip was used that interrogates 
≥47,000 target probes for genes obtained from the National Center for Bio­
technology Information Reference Sequence RefSeq Release 38 and other 
sources. Initial data analysis and quality control checks were performed using 
GenomeStudio software (Illumina). The data for all 12 samples was quantile 
normalized without background subtraction and exported as a project for 
additional analysis using Partek software (Genomic Suite v6.5). An ANOVA 
analysis was performed for all samples and heat maps were generated for 
genes with differential expression between B1 cell subsets. Data are publically 
available with accession no. GSE29717 at the Gene Expression Omnibus.
Photomicroscopy. Sort­purified B cells were cytocentrifuged (Shandon), 
stained with Wright­Giemsa, and imaged at 40× (Carl Zeiss). CD11b+ B1 cells 
stained  with  Hoechst  33342  were  single­cell  sorted  onto  an  Ampligrid 
(Beckman Coulter), excited by UV illumination, and imaged at 40×. Sort­
purified B cells for confocal imaging were fixed in paraformaldehyde, ad­
hered to poly­lysine–coated slides, excited at 488, 568, and 647 nm, and 
imaged at 60× (FluoView 300; Olympus).
B1 cell stimulation. CD20+CD27+CD43+CD11b human B1 cells were 
sort purified from adult peripheral blood and were cultured with PMA at 
100 ng/ml plus ionomycin at 400 ng/ml (P + I), SAC at 0.005% plus IL­2 at   
5 ng/ml (SAC + IL2), and anti­IgM at 7 µg/ml plus anti­CD40 at 10 µg/ml 
(IgM + CD40) in RPMI medium in round bottom wells.
Reagents. Fluorescently labeled antibodies (anti–CD5­PE­Cy7, anti–CD11b­
percp, anti–CD11b­PE, anti–CD11c­PE, anti–CD14­PE, anti–CD20­V450, 
anti–CD20­APC­Cy7,  anti–CD21­PE,  V500­streptavidin,  anti–CD23­PE, 
anti–CD27­V450,  anti–CD27­APC,  anti–CD43­FITC,  anti–CD70­PE, 
anti–CD86­PE, anti–CD86­biotin, anti–CD69­percp, anti–CD70­PE, anti–
CD71­PE, anti–CD80­PE, anti–IgD­PE, and anti–IgM­PE) were obtained 
from BD. Anti–CD11b­percp was obtained from Abcam. Anti­CD14 Alexa 
Fluor 647 was obtained from BioLegend. Anti­CD19 Alexa Fluor 488 and 
Alexa Fluor 568 streptavidin were obtained from Invitrogen. Anti–CD43­ 
biotin was obtained from Thermo Fisher Scientific. Anti–CD43­APC was 
obtained from eBioscience. Streptavidin was obtained from Biomeda. Anti­
CD86 neutralizing antibody was obtained from eBioscience. Wright­Giemsa 
stain was obtained from Ricca chemical.
Statistics. Statistical analysis was performed using Prism software (version 
5.0d for Mac). For calculation of fold change in SLE samples, the mean value 
These  characteristics  mirror  previous  findings  in  several 
mouse models of lupus, in which it has been shown that B1 
cell numbers are increased and antigen presentation is enhanced 
(Mohan et al., 1998; Xu et al., 2004; Duan and Morel, 2006), 
suggesting a pathogenic mechanism in which B1 cells present 
self­antigens  to  autoreactive  T  cells.  Although  it  might  be 
thought that the low frequency of CD11b+ B1 cells would be 
insufficient to substantially contribute to or alter immune ac­
tivity, large effects from small populations are well known in 
the immune system, such as the generation of natural IgM 
from mouse splenic B1 cells, the influence of human T reg 
cells  on  lupus  disease,  and  the  protection  from  pathogens   
afforded by myeloid dendritic cells (Barreto et al., 2009; 
Holodick et al., 2010; Kassianos et al., 2010; Hambleton et al., 
2011). Moreover, the full size of the human B1 cell population 
could well be larger than suggested by its circulating compo­
nent if one or more tissue reservoirs exist, as is the case with the 
preponderance of mouse B1 cells within the peritoneal cavity.
Thus, our results suggest that subdivision of human B1 cells 
into CD11b+ and CD11b populations is relevant not only for 
localizing activities that shape T cell function but for auto­
immune disease pathogenesis and pathopersistence as well. 
Identification of CD11b+ B1 cells as a new B cell type may pro­
vide an important foundation for understanding how B cells 
influence the immune response in both health and illness, and 
suggests a new target for selective therapy in autoimmune dis­
ease that will leave the bulk of B cell responses intact.
MATERIALS AND METHODS
Donors and samples. Adult peripheral blood samples were obtained by 
venipuncture of adult volunteers after obtaining informed consent in accor­
dance with the Declaration of Helsinki. Additional samples in the form of 
leukopacks were obtained from the New York Blood Center on the day of 
donation. These healthy controls were of mean age 51 yr, 78% female, 85% 
European, 13% Asian, and 2% Hispanic. Anonymous umbilical cord blood 
samples were obtained from the Tissue Donation Program at The Feinstein 
Institute for Medical Research. This study was approved by, and all samples 
were obtained in accordance with, the Institutional Review Board of the 
North Shore­LIJ Health System.
Processing. All blood samples were treated in a similar manner and pro­
cessed promptly upon receipt. Mononuclear cells were obtained by density 
gradient separation using lymphocyte separation medium (Cellgro). Except 
as otherwise noted, mononuclear cells were then washed and resuspended 
in RPMI 1640 (Cellgro) containing 10% fetal calf serum plus 2 mM   
l­glutamine, 10 mM Hepes, pH 7.25, 100 U/ml penicillin, and 100 µg/ml 
streptomycin.
B cell enrichment. For some experiments (Fig. 1 C; Fig. 2, A and B; Fig. 3 G; 
and Fig. 4 F), B cells were enriched by CD19 positive selection using the   
EasySep Human CD19+ B cell magnetic bead selection kit (STEMCELL Tech­
nologies) according to the manufacturer’s instructions. For some experiments 
(Fig. 1 D), B cells were enriched by CD20 positive selection using the EasySep 
Human CD20+ B cell magnetic bead selection kit (STEMCELL Technologies).
Cell sorting and flow cytometric analysis. Enriched B cells and mono­
nuclear cells were immunofluorescently stained and then sort purified on an 
Influx instrument (BD). Cells to be sorted were suspended in 2 mM EDTA 
in dye­free RPMI supplemented with 10% fetal calf serum at a concentra­
tion <50 million cells per milliliter. Flow cytometric analysis of immuno­
fluorescently stained cells was performed on an LSR­II instrument (BD). 2598 CD11b+ human B1 cells and lupus | Griffin and Rothstein
from the analyzed normal samples was calculated, and the values for the SLE 
samples were calculated as fold change from normal mean for each sample. 
For age and gender matching of controls to lupus, normal individuals with 
ages and gender matching the lupus patients were chosen at random in a 
blinded manner relative to B cell analysis results from the normal individuals 
to create a control population with the same gender frequency and mean age 
of the lupus patients.
Online supplemental material. Fig. S1 shows that sort­purified CD11b+ 
and CD11b B1 cells are singlets whose phenotype does not change with   
in vitro culture; that by direct visualization, CD11b+ B1 cells are singlets after 
sort purification; and that CD11b+ B1 cells display typical lymphocyte mor­
phology similar to other B cell populations. Table S1 shows lupus patient in­
formation.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20110978/DC1.
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